Table 1 Baseline patient-, donor- and transplant-related characteristics by graft-versus-host disease prevention strategy.
ATG based (N = 4140) | PTCy based (N = 1069) | p value | |
|---|---|---|---|
Medium follow up time years (CI 95%) | 2.2 (2.1–2.3) | 2 (1.9–2.1) | |
Patient Sex at Birth | |||
Male | 2426 (58.6%) | 628 (58.7%) | 0.93 |
Female | 1714 (41.4%) | 441 (41.3%) | |
Age at Transplant, yrs | |||
median [Q1, Q3] | 54.3 (43.7, 61.1) | 51.3 (39.0, 59.9) | <0.01 |
[Min, Max] | 18.0–77.7 | 18.0–75.6 | |
Donor Age | |||
median [Q1, Q3] | 52.3 (42.9, 59.6) | 49.1 (38.2, 57.6) | <0.01 |
[Min, Max] | 18.0–77.0 | 18.0–75.5 | |
Karnofsky | <0.01 | ||
<90 | 1171 (29.7%) | 249 (24.2%) | |
>= 90 | 2775 (70.3%) | 778 (75.8%) | |
Missing count | 194 | 42 | |
HCT Comorbidity Index | <0.01 | ||
0 | 2151 (59.8%) | 528 (52.5%) | |
1–2 | 720 (20.0%) | 228 (22.7%) | |
>=3 | 726 (20.2%) | 250 (24.9%) | |
Missing count | 543 | 63 | |
DRI | <0.01 | ||
Low | 216 (5.2%) | 104 (9.7%) | |
Int | 2829 (68.3%) | 687 (64.3%) | |
High | 938 (22.7%) | 242 (22.6%) | |
Very high | 157 (3.8%) | 36 (3.4%) | |
Hematological Malignancies | Not done | ||
AML | 2255 (54.5%) | 458 (42.8%) | |
MDS | 570 (13.8%) | 120 (11.2%) | |
ALL | 413 (10.0%) | 185 (17.3%) | |
NHL | 308 (7.4%) | 148 (13.8%) | |
MPN | 392 (9.5%) | 51 (4.8%) | |
MDS & MPN | 142 (3.4%) | 35 (3.3%) | |
Hodgkin’s Lymphoma | 60 (1.4%) | 72 (6.7%) | |
Transplant Year | <0.01 | ||
2017 | 903 (21.8%) | 147 (13.8%) | |
2018 | 890 (21.5%) | 194 (18.1%) | |
2019 | 848 (20.5%) | 233 (21.8%) | |
2020 | 719 (17.4%) | 236 (22.1%) | |
2021 | 780 (18.8%) | 259 (24.2%) | |
Myeloablative Conditioning | |||
No | 1865 (45.5%) | 472 (44.6%) | =0.61 |
Yes | 2234 (54.5%) | 586 (55.4%) | |
Missing count | 41 | 11 | |
TBI | < 0.011 | ||
No | 3629 (87.7%) | 800 (74.8%) | |
Yes | 511 (12.3%) | 269 (25.2%) | |
Cell Source | Not done | ||
BM | 159 (3.8%) | 131 (12.3%) | |
Cell SourcePB | 3981 (96.2%) | 938 (87.7%) | |
GVHD Prevention Regimen | |||
CSA + MTX | 1693 (40.9%) | 24 (2.2%) | |
CSA + MMF | 1335 (32.2%) | 209 (19.6%) | |
CSA only | 755 (18.2%) | 200 (18.7%) | |
TACRO + SIRO + MMF | 235 (5.7%) | 285 (26.7%) | |
TACRO + SIRO | 33 (0.8%) | 199 (18.6%) | |
TACRO + MTX | 34 (0.8%) | 2 (0.2%) | |
No additional drugs or other regimen | 55 (1.4%) | 150 (14.0%) | |
